JP5904518B2 - 免疫寛容誘導剤 - Google Patents

免疫寛容誘導剤 Download PDF

Info

Publication number
JP5904518B2
JP5904518B2 JP2014524635A JP2014524635A JP5904518B2 JP 5904518 B2 JP5904518 B2 JP 5904518B2 JP 2014524635 A JP2014524635 A JP 2014524635A JP 2014524635 A JP2014524635 A JP 2014524635A JP 5904518 B2 JP5904518 B2 JP 5904518B2
Authority
JP
Japan
Prior art keywords
iron
ala
immune tolerance
cells
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014524635A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2014010206A1 (ja
Inventor
田中　徹
徹 田中
元夫 中島
元夫 中島
史紀 安部
史紀 安部
直実 芳賀
直実 芳賀
高橋　究
究 高橋
秀典 伊東
秀典 伊東
康 梨井
康 梨井
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Center for Child Health and Development
SBI Pharmaceuticals Co Ltd
Original Assignee
National Center for Child Health and Development
SBI Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Center for Child Health and Development, SBI Pharmaceuticals Co Ltd filed Critical National Center for Child Health and Development
Application granted granted Critical
Publication of JP5904518B2 publication Critical patent/JP5904518B2/ja
Publication of JPWO2014010206A1 publication Critical patent/JPWO2014010206A1/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C12N5/064—Immunosuppressive dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/052—Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2014524635A 2012-07-13 2013-07-03 免疫寛容誘導剤 Active JP5904518B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012157374 2012-07-13
JP2012157374 2012-07-13
PCT/JP2013/004130 WO2014010206A1 (ja) 2012-07-13 2013-07-03 免疫寛容誘導剤

Publications (2)

Publication Number Publication Date
JP5904518B2 true JP5904518B2 (ja) 2016-04-13
JPWO2014010206A1 JPWO2014010206A1 (ja) 2016-06-20

Family

ID=49915689

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014524635A Active JP5904518B2 (ja) 2012-07-13 2013-07-03 免疫寛容誘導剤

Country Status (8)

Country Link
US (1) US9399029B2 (de)
EP (1) EP2873417B1 (de)
JP (1) JP5904518B2 (de)
CN (2) CN104411306B (de)
HU (1) HUE043511T2 (de)
PL (1) PL2873417T3 (de)
TW (1) TWI619493B (de)
WO (1) WO2014010206A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013054470A1 (ja) * 2011-10-12 2013-04-18 Ｓｂｉファーマ株式会社 移植臓器生着促進剤
WO2014013664A1 (ja) * 2012-07-19 2014-01-23 Ｓｂｉファーマ株式会社 インフルエンザウイルス感染症の予防・治療剤
WO2019141731A1 (en) 2018-01-18 2019-07-25 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Langerin+ cell targeting
GB201905940D0 (en) * 2019-04-29 2019-06-12 Intract Pharma Ltd 5-aminolevulinic acid for the local treatment of inflammatory bowel disease
US20240189269A1 (en) * 2021-03-26 2024-06-13 Tokyo Institute Of Technology Pharmaceutical composition for suppressing tmprss2 expression
CN113181153B (zh) * 2021-05-31 2023-03-31 北京大学人民医院 柠檬酸在制备预防和/或治疗自身免疫病的药物中的应用
CA3253222A1 (en) * 2022-03-01 2025-07-04 Sbi Pharmaceuticals Co., Ltd. PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF AUTOIMMUNE DISEASES

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508864A (ja) * 2001-06-01 2005-04-07 ナショナル・ジュウィッシュ・メディカル・アンド・リサーチ・センター 糖尿病の治療、または移植術における使用、または免疫寛容の誘導のためのオキシダントスカベンジャー
JP2006069963A (ja) * 2004-09-02 2006-03-16 Cosmo Oil Co Ltd 抗酸化機能向上剤
WO2010050179A1 (ja) * 2008-10-27 2010-05-06 Ｓｂｉアラプロモ株式会社 ５－アミノレブリン酸若しくはその誘導体、又はそれらの塩を有効成分とする成人病の予防・改善剤
JP4547174B2 (ja) * 2003-03-18 2010-09-22 協和発酵キリン株式会社 免疫制御性樹状細胞の調製法およびその用途
JP2011016753A (ja) * 2009-07-08 2011-01-27 Sbi Alapromo Co Ltd ５−アミノレブリン酸若しくはその誘導体、又はそれらの塩を有効成分とするがんの予防・改善剤
WO2011048766A1 (ja) * 2009-10-21 2011-04-28 国立大学法人愛媛大学 自己免疫疾患治療に用いる新規抗原としての炭酸脱水酵素ｉ
WO2011105394A1 (ja) * 2010-02-23 2011-09-01 日本化薬株式会社 制御性樹状細胞の作製方法
WO2011145343A1 (ja) * 2010-05-19 2011-11-24 Ｓｂｉアラプロモ株式会社 ５－アミノレブリン酸又はその誘導体を有効成分とする抗マラリア薬

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9302431D0 (sv) 1993-07-16 1993-07-16 Ab Astra Use of indenoindole compounds
US5756492A (en) 1996-09-09 1998-05-26 Sangstat Medical Corporation Graft survival prolongation with porphyrins
JP4590041B2 (ja) 1998-12-24 2010-12-01 株式会社林原生物化学研究所 臓器保存剤
JP5230042B2 (ja) 1999-06-02 2013-07-10 株式会社ビーエムジー 動物の細胞または臓器の保存剤およびその保存方法。
AU2001253400B2 (en) 2000-04-11 2007-03-01 University Of Southern California A method to prevent graft rejection using tgf-beta to induce t suppressor cells
JP2002060301A (ja) 2000-08-17 2002-02-26 Seikagaku Kogyo Co Ltd 臓器保存液
US20040171601A1 (en) * 2002-07-31 2004-09-02 Dai Fukumura Photodynamic and sonodynamic therapy
US20050032210A1 (en) * 2003-03-18 2005-02-10 Kirin Beer Kabushiki Kaisha Method of preparing immuno-regulatory dendritic cells and the use thereof
US20040235162A1 (en) 2003-03-18 2004-11-25 Kirin Beer Kabushiki Kaisha Method of preparing immunoregulatory dendritic cells and the use thereof
JP2004300098A (ja) 2003-03-31 2004-10-28 Oxygenix:Kk 移植用臓器の処理方法
JP2005306749A (ja) 2004-04-19 2005-11-04 Kringle Pharma Inc Ｈｇｆ含有臓器保存液
ES2459366T3 (es) 2004-09-02 2014-05-09 Cosmo Oil Co., Ltd. Agentes mejoradores de la función constitutiva
JP4814567B2 (ja) 2004-09-02 2011-11-16 コスモ石油株式会社 健康機能向上剤
JP4919453B2 (ja) 2005-04-07 2012-04-18 独立行政法人理化学研究所 炎症性疾患の予防又は治療剤
MX2007013623A (es) * 2005-04-28 2008-02-12 Cosmo Oil Co Ltd Preparacion externa para la piel.
JP2006316000A (ja) 2005-05-12 2006-11-24 Vitamin C60 Bioresearch Kk 血液または臓器の保存剤と保存方法
JP2007131598A (ja) 2005-11-14 2007-05-31 Kurosu Biotech:Kk 腎移植拒絶反応抑制剤
WO2007100154A1 (ja) * 2006-03-03 2007-09-07 Riken アレルギー疾患に対する制御性樹状細胞を用いた免疫細胞療法
JP5150091B2 (ja) 2006-11-01 2013-02-20 日本澱粉工業株式会社 低酸素状態下での細胞及び心臓保存剤
CA2706458A1 (en) 2007-11-30 2009-06-11 Therakos, Inc. Process for reducing effects of graft versus host disease using ex vivo expanded cd4+cd25+ regulatory t cells
JP2009221128A (ja) 2008-03-14 2009-10-01 Seizo Fujikawa 臓器保存液および臓器保存方法
EP2305237B1 (de) * 2008-05-14 2014-04-30 SBI Pharmaceuticals Co., Ltd. Therapeutisches mittel für die männliche sterilität
AU2009256014A1 (en) 2008-06-06 2009-12-10 Baylor Research Institute Respiratory syncytial virus renders dendritic cells tolerogenic
JP5295652B2 (ja) 2008-06-16 2013-09-18 Ｓｂｉファーマ株式会社 光障害の軽減剤
JP2009143939A (ja) * 2009-01-27 2009-07-02 Tsujido Chemical Corp 治療剤
EP2722041B1 (de) 2011-06-16 2018-10-24 SBI Pharmaceuticals Co., Ltd. Therapeutischer wirkstoff gegen allergische rhinitis
WO2013054470A1 (ja) * 2011-10-12 2013-04-18 Ｓｂｉファーマ株式会社 移植臓器生着促進剤
JP5369206B2 (ja) * 2012-03-08 2013-12-18 コスモ石油株式会社 ５−アミノレブリン酸塩酸塩の製造方法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508864A (ja) * 2001-06-01 2005-04-07 ナショナル・ジュウィッシュ・メディカル・アンド・リサーチ・センター 糖尿病の治療、または移植術における使用、または免疫寛容の誘導のためのオキシダントスカベンジャー
JP4547174B2 (ja) * 2003-03-18 2010-09-22 協和発酵キリン株式会社 免疫制御性樹状細胞の調製法およびその用途
JP2006069963A (ja) * 2004-09-02 2006-03-16 Cosmo Oil Co Ltd 抗酸化機能向上剤
WO2010050179A1 (ja) * 2008-10-27 2010-05-06 Ｓｂｉアラプロモ株式会社 ５－アミノレブリン酸若しくはその誘導体、又はそれらの塩を有効成分とする成人病の予防・改善剤
JP2011016753A (ja) * 2009-07-08 2011-01-27 Sbi Alapromo Co Ltd ５−アミノレブリン酸若しくはその誘導体、又はそれらの塩を有効成分とするがんの予防・改善剤
WO2011048766A1 (ja) * 2009-10-21 2011-04-28 国立大学法人愛媛大学 自己免疫疾患治療に用いる新規抗原としての炭酸脱水酵素ｉ
WO2011105394A1 (ja) * 2010-02-23 2011-09-01 日本化薬株式会社 制御性樹状細胞の作製方法
WO2011145343A1 (ja) * 2010-05-19 2011-11-24 Ｓｂｉアラプロモ株式会社 ５－アミノレブリン酸又はその誘導体を有効成分とする抗マラリア薬

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6015041638; Ｊｏｕｒｎａｌ　ｏｆ　Ｄｅｒｍａｔｏｌｏｇｙ ３４（５）, 2007, ｐ．３２０-３２７ *
JPN6015041642; Ｉｍｍｕｎｏｐｈａｒｍａｃｏｌｏｇｙ ４０（３）, 1998, ｐ．２３１-２４０ *
JPN6015041645; Ｂｒｉｔｉｓｈ　Ｊｏｕｒｎａｌ　ｏｆ　Ｄｅｒｍａｔｏｌｏｇｙ １６５（３）, 2011, ｐ．５１３-５１９ *
JPN6015041648; 化学と生物 ４８（６）, 2010, ｐ．３８９-３９４ *

Also Published As

Publication number Publication date
HUE043511T2 (hu) 2019-08-28
EP2873417A1 (de) 2015-05-20
CN104411306A (zh) 2015-03-11
HK1204285A1 (en) 2015-11-13
US9399029B2 (en) 2016-07-26
HK1205950A1 (en) 2015-12-31
WO2014010206A1 (ja) 2014-01-16
JPWO2014010206A1 (ja) 2016-06-20
EP2873417B1 (de) 2019-03-06
CN106474098B (zh) 2020-06-05
TW201408285A (zh) 2014-03-01
PL2873417T3 (pl) 2019-09-30
TWI619493B (zh) 2018-04-01
US20150174090A1 (en) 2015-06-25
EP2873417A4 (de) 2016-03-09
CN106474098A (zh) 2017-03-08
CN104411306B (zh) 2017-05-24

Similar Documents

Publication Publication Date Title
JP5904518B2 (ja) 免疫寛容誘導剤
JP6172724B2 (ja) 免疫寛容の誘導促進剤
CN104487066B (zh) 放射线损害的预防和/或治疗剂
HK1232794A1 (en) Immune tolerance inducer
HK1205950B (en) Immune tolerance inducer
HK1204285B (en) Immune tolerance inducer
HK1226665A1 (en) Enhancer of survival of transplanted organ
HK1195008B (en) Enhancer of survival of transplanted organ
HK1206987B (zh) 放射线损害的预防和/或治疗剂

Legal Events

Date Code Title Description
TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160301

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160308

R150 Certificate of patent or registration of utility model

Ref document number: 5904518

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250